Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons.
Amita Gupta and colleagues discuss priorities in clinical research aimed at improving tuberculosis prevention and treatment in pregnant women, children, and people with HIV.
Main Authors: | Amita Gupta, Michael D Hughes, Anthony J Garcia-Prats, Katherine McIntire, Anneke C Hesseling |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-08-01
|
Series: | PLoS Medicine |
Online Access: | https://doi.org/10.1371/journal.pmed.1002882 |
Similar Items
-
ANTITUBERCULOSIS DRUG DOSAGE FORMS: RANGE, KEY BENEFITS AND PROSPECTS OF TECHNOLOGICAL IMPROVEMENT
by: M. E. Kim, et al.
Published: (2016-09-01) -
A Study of Embryotoxic, Foetotoxic, and Teratogenic Effects of the Original Antituberculosis Agent Thiozonide in Pregnant Rabbits
by: A. Yu. Borodina, et al.
Published: (2023-06-01) -
Visual design for the modern web /
by: 252948 McIntire, Penny
Published: (2008) -
Physiological impacts of beech leaf disease across a gradient of symptom severity among understory American beech
by: Cameron D. McIntire
Published: (2023-03-01) -
Analysis of the clinical antibacterial and antituberculosis pipeline
by: Theuretzbacher, U, et al.
Published: (2018)